Compositions, uses, and preparation of platelet lysates

Patent metadata

Field	Value
Publication number	US-9688959-B2
Application number	US-201214129448-A
Country	US
Kind code	B2
Filing date	Jun 26, 2012
Priority date	Jun 27, 2011
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method.

First claim

What we claim:

1. A composition comprising heparin, heparin-stabilized growth factors and components from a lysate of plateletpheresis products, wherein the composition comprises a concentration of fibrinogen of less than 50 μg/ml and a concentration of PDGF-BB greater than 10 ng/mL.

2. The composition of claim 1 , wherein the composition is substantially depleted of fibrinogen.

3. The composition of claim 1 , wherein the platelet lysate components are not substantially depleted of PDGF.

4. The composition of claim 1 , wherein the composition is an aqueous solution.

5. The composition of claim 4 , wherein the concentration of fibrinogen is less than 4 μg/mL.

6. The composition of claim 1 , wherein the concentration of fibrinogen is less than 10 μg/ml.

7. The composition of claim 1 , wherein the concentration of fibrinogen is less than 2 μg/ml.

8. The composition of claim 1 , wherein the composition is substantially free of cryoprecipitate.

9. The composition of claim 1 , further comprising cell culture medium components.

10. The composition of claim 1 , wherein the composition is substantially free of cell debris.

11. The composition of claim 1 , further comprising a calcium salt.

12. The composition of claim 11 , wherein the calcium salt is dissolved in a buffer or an isotonic electrolyte solution.

13. The composition of claim 11 , wherein the calcium salt is calcium chloride.

14. A composition made by the processes of removing water from a composition of claim 4 .

15. A method of culturing cells, wherein cells are cultured in a medium comprising the composition of claim 1 .

16. The method of claim 15 , wherein the cells are progenitor cells or stem cells.

17. The method of claim 16 , wherein the stem cells are pluripotent stem cells, multipotent stem cells, somatic stem cells, mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, dental pulp stem cell, embryonic stem cells, bone marrow or hematopoietic stem cell, amniotic stem cells, lymphoid or myeloid stem cells.

18. A method of treating a wound or wound closure comprising applying a composition comprising a composition of claim 1 to the wound.

19. A wound dressing comprising a composition of claim 1 .

20. The wound dressing of claim 19 selected from a bandage, gauze, cyanoacrylate glue, or suture.

21. The wound dressing of claim 19 further comprising an antibiotic.

Assignees

• Copland Ian B
• Galipeau Jacques
• Univ Emory
• Children'S Healthcare Of Atlanta Inc

Inventors

• Copland Ian B
• Galipeau Jacques

Classifications

• A61P27/02

  Ophthalmic agents · CPC title

• C12N5/0668

  Mesenchymal stem cells from other natural sources · CPC title

• A61L15/44

  Medicaments · CPC title

• A61L24/0005

  Ingredients of undetermined constitution or reaction products thereof · CPC title

• A61L15/40

  containing ingredients of undetermined constitution or reaction products thereof {, e.g. plant or animal extracts} · CPC title